Other clinical trials in which participants were enrolled with disturbed glucose homeostasis, such as patients with T2D, the metabolic syndrome, or decreased insulin sensitivity, also did not find improvement in IHL upon resveratrol treatment (14, 36, 45, 46). The gene discussed is INS; the disease is metabolic syndrome.